NSCLC
Aug 04, 2017
CDK 4/6 Inhibitors- The Changing Paradigm for Breast Cancer Treatment
The discovery of Cyclin Dependent Kinases (CDKs) is a result of increasing number of cancer cases worldwide. The development of CDKs has changed the paradigm for cancer treatment and it has gradually become an interesting area of research in oncology. The research on CDK inhibitors gained momentum because of the fre...
Read More...
May 04, 2017
Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal
Merck beats Q1 estimates as Keytruda sales double Merck is the victim of its own success, judging from its first-quarter report. The company beat sales and earnings estimates, and it upped its guidance for the year, despite some significant suffering from generic competition. Sales of its hit immuno-oncology drug Ke...
Read More...
Apr 27, 2017
Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A
Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
